Merck Expands Singapore Lab to Bolster Biosafety Testing in Asia Pacific
Merck, a science and technology company, is expanding its biosafety testing laboratory in Singapore to bolster services across the Asia Pacific region. The lab will provide advanced analytical and biosafety testing services for customers in the area, including cell line characterization and GMP next-generation sequencing capabilities.
The expanded facility aims to support the industry's shift towards state-of-the-art quality control testing of biologics and 3Rs (Replacement, Reduction, and Refinement of animal use) through advanced molecular methods. The Singapore BioReliance lab was opened in 2018, and the expansion will bring the total lab area to over 1,000 square meters.
'Localizing these BioReliance testing capabilities means our Asia Pacific biopharma customers can accelerate their development timelines, improve operational efficiency, and meet evolving regulatory and sustainability standards,' said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck. The expansion is also a key step in Merck's broader strategy to support the region's dynamic life science ecosystem and drive scientific progress.